Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 918 of 6351
-
Can a new pill tame blood sugar in type 2 diabetes?
Disease control CompletedThe goal of this clinical trial is to evaluate the efficacy and safety of berberine ursodeoxycholate (HTD1801) compared to placebo in patients with type 2 diabetes inadequately controlled with diet and exercise alone.
Phase 2 • Sponsor: Shenzhen HighTide Biopharmaceutical Ltd. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New pill targets tough cancers: early trial underway
Disease control OngoingBDTX-1535-101 is an open-label, Phase 1 dose escalation and Phase 2 multiple cohort study designed to evaluate the safety, pharmacokinetics (PK), optimal dosage, central nervous system (CNS) activity, and antitumor activity of silevertinib (BDTX-1535). The study population compri…
Phase 1/2 • Sponsor: Black Diamond Therapeutics, Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could a simple stool test spot cancer early in lynch syndrome patients?
Diagnosis Recruiting nowThis study collects blood and stool samples from patients with suspected or diagnosed Lynch syndrome to evaluate a deoxyribonucleic acid (DNA) screening technique for the detection of colorectal cancer in Lynch syndrome patients.
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Aug 20, 2026 00:00 UTC
-
New variant-targeted COVID boosters show promise in large trial
Vaccine CompletedThis phase 2 clinical trial will evaluate the safety and immunogenicity of additional doses of prototype and variant (alone or in combination) vaccine candidates in previously vaccinated participants with or without prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
Phase 2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Jun 27, 2026 07:55 UTC
-
New drug targets genetic kidney disease in landmark trial
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.
Phase 2/3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Sep 10, 2026 01:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat lung cancer before surgery
Disease control OngoingThis is a phase II, single-arm, open-label study evaluating the efficacy, safety and tolerability of neoadjuvant sotorasib in combination with cisplatin (or carboplatin) and pemetrexed chemotherapy for patients with surgically resectable stage IIA - IIIB (T3-T4/N2) (based on AJCC…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Extended drug regimen may shield transplant patients from deadly immune attack
Disease control Recruiting nowThis is a multicenter randomized, double blind, Phase 2 trial for patients receiving transplants from 7 of 8 HLA matched donors, in which an extended dosing regimen of abatacept, and a short-term dosing regimen + placebo, when added to standard calcineurin inhibitor + methotrexat…
Phase 2 • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Can a sleep pill boost success in opioid treatment?
Disease control CompletedThis is a 4-week, randomized-controlled trial of suvorexant vs placebo in persons with opioid use disorder who have recent fentanyl exposure. Participants will first undergo a 5-day residential phase wherein participants are stabilized on sublingual buprenorphine/naloxone, follow…
Phase 2 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a nanoparticle vaccine stop the virus behind mono and some cancers?
Vaccine CompletedBackground: Epstein-Barr virus (EBV) causes most cases of infectious mononucleosis (mono). Up to 1 in 10 people who get mono can have fatigue that lasts more than 6 months. One out of 100 people can have severe complications. EBV is also associated with several types of cancer. …
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Vaccine
Last updated Aug 15, 2026 00:00 UTC
-
New NanoKnife treatment shows promise for prostate cancer
Disease control CompletedPivotal study to evaluate the use of the NanoKnife System as a focal therapy option for prostate cancer patients. This study will assess the safety and effectiveness of the device when used to ablate prostate tissue in intermediate-risk prostate cancer patients.
Sponsor: Angiodynamics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo aims to halt tough prostate cancer
Disease control Recruiting nowThis phase II trial tests whether cabozantinib and atezolizumab work to shrink tumors in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes need…
Phase 2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug aims to slow lung damage in rare autoimmune disease
Disease control OngoingThe purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.
Phase 2 • Sponsor: Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can a smart drug deliver a One-Two punch to advanced cancers?
Disease control PausedThis is a first-in-human (FIH) study to evaluate the safety and preliminary efficacy of experimental drug CS5001 used as a single agent and in combination with systemic therapies in patients with advanced hematological and solid tumors.
Phase 1 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New pill could cut blood transfusions for blood disorders
Disease control CompletedThis clinical trial is a Phase 2 study that will evaluate the safety and clinical activity of etavopivat in patients with thalassemia or sickle cell disease and test how well etavopivat works to lower the number of red blood cell transfusions required and increase hemoglobin.
Phase 2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Promising drug may slow blindness in teens with rare eye disease
Disease control CompletedThe primary objective of this trial is to assesses the efficacy of tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1
Phase 3 • Sponsor: Belite Bio, Inc • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New kidney drug could help kids with protein leak
Disease control OngoingResearchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine. The kidneys filter waste and fluid from the blood to form ur…
Phase 3 • Sponsor: Bayer • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Magic mushroom compound shows promise for Hard-to-Treat depression and suicidal thoughts
Symptom relief CompletedThis study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation
Phase 2 • Sponsor: Sheppard Pratt Health System • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
Blood test could spot lung cancer return risk after surgery
Disease control Recruiting nowThis is a study to look at whether the presence of circulating tumour DNA (ctDNA) in the blood can help to predict whether giving adjuvant treatment after surgery can decrease the chance of the cancer coming back in people with lung cancer.
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
A new imaging agent could tell doctors which liver cancers will resist immunotherapy
Diagnosis Recruiting nowThis prospective clinical trial will evaluate PET/CT and genomic liquid biopsy based biomarkers as predictors of clinical therapeutic response to immune-checkpoint inhibitor (ICI) therapy for patients with inoperable hepatocellular carcinoma (HCC). The primary objective of this d…
Phase 2 • Sponsor: Queen's Medical Center • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
New cocktail of drugs shows promise for nasopharyngeal cancer
Disease control Recruiting nowThe investigators hypothesize that the addition of bevacizumab and pembrolizumab to induction cisplatin and gemcitabine is tolerable and improves metabolic complete response (mCR), relapse free survival (RFS) and overall survival (OS) compared to induction cisplatin and gemcitabi…
Phase 2 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC